Health Canada is currently assessing nine submissions for generic versions of well-known weight loss medications, a move that experts believe could potentially reduce costs. The submissions pertain to generic variations of semaglutide, the key component in Novo Nordisk’s injectable drugs Ozempic and Wegovy, which have received approval in Canada for treating diabetes and aiding weight loss. These medications belong to the class of glucagon-like peptide-1 (GLP-1) therapies, which mimic a natural gut hormone to regulate blood sugar levels, slow digestion, and enhance satiety. Common side effects of semaglutide include nausea, vomiting, diarrhea, stomach pain, fatigue, constipation, and headaches.
Canada stands out as the sole country where Novo Nordisk has allowed the patent for its semaglutide drugs to expire, leading to the end of “regulatory exclusivity” on January 4. Consequently, Canada may become the first nation to offer more affordable versions of Ozempic and Wegovy to patients with prescriptions, although immediate availability is uncertain.
The recent approval of a pill form of Wegovy in the United States by Novo Nordisk marks a significant development. While details on the availability of this pill in Canada remain unclear, Health Canada and Novo Nordisk are being queried on this matter. Furthermore, Novo Nordisk already offers a pill, Rybelsus, approved by Health Canada for treating Type 2 diabetes, which also contains semaglutide.
Generics, deemed equivalent to brand name drugs by Health Canada, undergo rigorous evaluation to ensure safety, quality, and effectiveness. The evaluation process for generic semaglutide drugs is notably intricate due to their complex synthetic nature compared to other medications. The expiration of patents enables other companies to produce drug copies at lower costs, potentially impacting drug safety and efficacy. Pricing of these generic drugs is influenced by various factors, including formulation, dosing, and market competition.
Experts anticipate that the availability of cheaper generic versions may take time to materialize, with potential approval not expected until later in the year. The introduction of more affordable alternatives could significantly benefit patients in Canada, particularly those facing financial constraints in accessing essential obesity medications. Companies such as Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada are among those seeking Health Canada’s review for generic submissions.